Got in at $0.798 average. www.globenewswire.com www.globenewswire.com
A short at 3.16 to 2.30 with the necessary risk management will bring a 26.96% return
The five-year mortality rate for women with metastasized breast cancer is 30%. However, that statistic figure may soon be curbed due to Allarity Therapeutics, Inc.’s (NASDAQ: ALLR) new treatment – IXEMPRA-DRP. This is a treatment system combining Ixempra, an FDA-approved treatment for Metastasized breast cancer, with DRP, an AI system that matches patients with...
As with most micro biotech companies, I expect the price to continue to fall to the $1 region and then “flatten out” for a while to keep its head just above the minimum listing requirement. It will then probably remain there until it is seemingly forgotten. Then, in a move to regain compliance (if it falls below $1) we can expect some financial reorganisation on...
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology,